{"id":54616,"date":"2022-12-01T09:00:00","date_gmt":"2022-12-01T08:00:00","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=54616"},"modified":"2024-08-16T23:26:16","modified_gmt":"2024-08-16T21:26:16","slug":"getting-closer-to-stopping-toxoplasmosis-infection","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/","title":{"rendered":"Getting closer to stopping toxoplasmosis infection"},"content":{"rendered":"\n<p><em>Toxoplasma gondii<\/em>, <em>Plasmodium falciparum, Cryptosporidium<\/em> \u2013 these parasites of the Apicomplexa family,&nbsp; respectively responsible for toxoplasmosis, malaria and cryptosporidiosis \u2014 are still a major issue for public health. Few effective drugs are available, many of which have serious side effects, and immunosuppressed people are particularly susceptible to toxoplasmosis. Drug resistance adds another level of complexity, particularly in the case of malaria, a disease that causes a <a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria#:~:text=Malaria%20is%20a%20life%2Dthreatening,at%20627%20000%20in%202020.\" target=\"_blank\" rel=\"noreferrer noopener\">large number of deaths worldwide<\/a>.<\/p>\n\n\n\n<p>To tackle these problems, the Institute of Advanced Biosciences (IAB), has led a drug repurposing strategy in collaboration with EMBL Grenoble, targeting the parasite <em>Toxoplasma gondii<\/em>. The study aimed to identify a potential drug molecule that could be repurposed to stop the infection mechanism, by screening a large library of already approved drugs.<\/p>\n\n\n\n<p>This study, published in <a href=\"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.abn3231\" target=\"_blank\" rel=\"noreferrer noopener\"><em>Science Translational Medicine<\/em><\/a>, sheds light on how Altiratinib&nbsp; \u2013&nbsp; a drug currently used to treat glioblastoma \u2013 perfectly binds a <em>T. gondii<\/em> protein called PRP4 kinase, preventing the parasite from proliferating inside the human body.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>MASSIF-1, the perfect match<\/strong><\/h2>\n\n\n\n<p>Mohamed-Ali Hakimi, a researcher at the IAB and corresponding author of the study, has been working on <em>T. gondii<\/em> with his team for over 20 years, from reprogramming its sexual stages to studying host-pathogen interactions and looking for effective drugs.<\/p>\n\n\n\n<p>Benefiting from a long-standing collaboration with EMBL Grenoble researcher Matthew Bowler on various aspects of this pathogen and its interactions with the host, and from the complementarity of expertises between IAB and EMBL Grenoble, Hakimi and Bowler initiated studies on available drugs that could be repurposed to block the parasite\u2019s infection mechanisms.<\/p>\n\n\n\n<p>EMBL Grenoble\u2019s expertise in structural biology research and scientific services has been particularly crucial in this drug repurposing strategy. Always at the forefront of technology developments to automate processes in crystallography and structure determination, EMBL Grenoble offers instruments and facilities particularly useful for large-scale drug screening, like the High-Throughput Crystallisation Facility (HTX) and the completely automated beamline MASSIF-1 jointly operated by EMBL and the ESRF.<\/p>\n\n\n\n<p>\u201cThe advantage with MASSIF-1 is that we can get the information extremely quickly and easily. Years ago, obtaining a single structure would be the work of a PhD thesis or a much longer project. Christopher Swale, post-doctoral fellow at IAB and first author of this publication, used the HTX technology and MASSIF-1 at EMBL Grenoble, and obtained within two weeks the first structure of the target enzyme showing where the drug binds,\u201d said Matthew Bowler, beamline scientist in charge of MASSIF-1 and one of the authors of the publication.<\/p>\n\n\n\n<p>The rapidity of the automated processes of EMBL\u2019s scientific services allows researchers to try different experimental conditions and optimise settings. &#8220;Thanks to this collaboration with EMBL experts, we&#8217;re going beyond technical and technological boundaries. We also have enriching exchanges about biological questions to see how we can make improvements,\u201d said Hakimi.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Finding the perfect fit against <em>Toxoplasma gondii<\/em><\/strong><\/h2>\n\n\n\n<p>In this study, the researchers not only identified Altiratinib as a potential blocker of the parasite\u2019s infection but also obtained a high resolution 3D structure that shows how the&nbsp; drug binds to the PRP4 kinase protein of <em>T. gondii<\/em>.<\/p>\n\n\n\n<p>The added value of identifying where the drug precisely binds to the pathogen protein lies in allowing comparisons with how it binds to the similar version of the protein in humans and if it would affect its function in the same way. This \u2018affinity selectivity\u2019 of the drug on the pathogen versus the human target is particularly important to specifically target the pathogen and avoid serious side effects in humans when administering the drug.<\/p>\n\n\n\n<p>In the case of Altiratinib, the study confirms that the molecule has a better affinity selectivity on <em>T. gondii<\/em> PRP4 kinase over the human PRP4 kinase. This enzyme is involved in the RNA splicing mechanism \u2013 an important step in gene expression in which specific segments of RNAs are removed in order for the cell to keep the necessary information to produce proteins. In simple terms, disturbing the splicing function in the parasite stops the infection process.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Identifying treatment options against malaria<\/strong><\/h2>\n\n\n\n<p>This discovery is opening up effective antiparasitic drug treatment options against <em>T. gondii<\/em>, and by extension, against other apicomplexan parasites including <em>Plasmodium falciparum, <\/em>which causes Malaria. Even though Altiratinib is less effective on<em> P. falciparum<\/em>, it could be paired with the molecule TCMDC-135051, found to target the same kinase by a research team from the Medicines for Malaria Venture (MMV) consortium and currently under clinical trials.<\/p>\n\n\n\n<p>In this study, IAB researchers realised through simulations that even though Altiratinib and TCMDC-135051 bind to the same target, they have different mechanisms of action. This could open up the possibility of developing bi-therapy treatment to counter drug resistance in malaria.<\/p>\n\n\n\n<p>IAB and EMBL Grenoble researchers will continue to work on drug repurposing strategies against these parasites. Further experiments will take advantage of <a href=\"https:\/\/www.embl.org\/news\/lab-matters\/two-in-one-combining-massif-1-and-crystaldirect\/\">a new configuration of the MASSIF-1 beamline<\/a> with the <em>CrystalDirect<\/em> technology, allowing the complete automation of room temperature experiments. This new modality, difficult to perform manually, could give additional hints towards potential drug treatments.<\/p>\n\n\n\n<p>In the context of the <a href=\"https:\/\/www.embl.org\/about\/programme\/\">EMBL\u2019s new programme \u2018Molecules to Ecosystems\u2019<\/a>, EMBL Grenoble is pushing the frontiers of structural biology technology, research, and services with a strong focus on <a href=\"https:\/\/www.embl.org\/about\/programme\/research-plans\/infection-biology\/\">Infection Biology<\/a> and drug development.<br \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recent studies supported by EMBL Grenoble\u2019s expertise in structural biology research and scientific services have identified Altiratinib as a potential drug to stop toxoplasmosis infection and opened up treatment options against malaria.<\/p>\n","protected":false},"author":104,"featured_media":54668,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2,17591],"tags":[726,37,3684,253,411,4726,35,1770,4724,13964,1714],"embl_taxonomy":[9792],"class_list":["post-54616","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science","category-science-technology","tag-beamline","tag-grenoble","tag-infection-biology","tag-massif-1","tag-mccarthy","tag-parasite","tag-structural-biology","tag-technology","tag-toxoplasma","tag-userstory","tag-x-ray-crystallography","embl_taxonomy-embl-grenoble"],"acf":{"featured":true,"show_featured_image":false,"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"article_intro":"<p>Recent studies supported by EMBL Grenoble\u2019s expertise in structural biology have identified Altiratinib as a potential drug to stop toxoplasmosis infection and opened up treatment options against malaria<\/p>\n","related_links":[{"link_description":"Institute for Advanced Biosciences","link_url":"https:\/\/iab.univ-grenoble-alpes.fr\/?language=en"},{"link_description":"EMBL Grenoble\u2019s scientific services and facilities","link_url":"https:\/\/www.embl.org\/services-facilities\/grenoble\/"}],"source_article":[{"publication_title":"Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase","publication_link":{"title":"","url":"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.abn3231","target":""},"publication_authors":"Swale C., et al.","publication_source":"Science Translational Medicine","publication_date":" 3 August 2022","publication_doi":""}],"in_this_article":false,"press_contact":"None","article_translations":false,"languages":""},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"b14d3f13-5670-44fb-8970-e54dfd9c921a\";i:1;s:36:\"89e00fee-87f4-482e-a801-4c3548bb6a58\";i:2;s:36:\"8f81131e-d37c-470c-848f-618fce652295\";}","parents":[],"name":["EMBL Grenoble"],"slug":"embl-grenoble","description":"Where &gt; All EMBL sites &gt; EMBL Grenoble"}],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Getting closer to stopping toxoplasmosis infection | EMBL<\/title>\n<meta name=\"description\" content=\"Recent studies supported by EMBL Grenoble\u2019s expertise in structural biology have identified Altiratinib as a potential drug to stop toxoplasmosis infection and opened up treatment options against malaria\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Getting closer to stopping toxoplasmosis infection | EMBL\" \/>\n<meta property=\"og:description\" content=\"Recent studies supported by EMBL Grenoble\u2019s expertise in structural biology have identified Altiratinib as a potential drug to stop toxoplasmosis infection and opened up treatment options against malaria\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-01T08:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-16T21:26:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Myl\u00e8ne Andr\u00e9\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Myl\u00e8ne Andr\u00e9\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/\"},\"author\":{\"name\":\"Myl\u00e8ne Andr\u00e9\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/845a38992ad0698d457ec1dd32d13c79\"},\"headline\":\"Getting closer to stopping toxoplasmosis infection\",\"datePublished\":\"2022-12-01T08:00:00+00:00\",\"dateModified\":\"2024-08-16T21:26:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/\"},\"wordCount\":873,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg\",\"keywords\":[\"beamline\",\"grenoble\",\"infection biology\",\"massif-1\",\"mccarthy\",\"parasite\",\"structural biology\",\"technology\",\"toxoplasma\",\"userstory\",\"x-ray crystallography\"],\"articleSection\":[\"Science\",\"Science &amp; Technology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/\",\"url\":\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/\",\"name\":\"Getting closer to stopping toxoplasmosis infection | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg\",\"datePublished\":\"2022-12-01T08:00:00+00:00\",\"dateModified\":\"2024-08-16T21:26:16+00:00\",\"description\":\"Recent studies supported by EMBL Grenoble\u2019s expertise in structural biology have identified Altiratinib as a potential drug to stop toxoplasmosis infection and opened up treatment options against malaria\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg\",\"width\":1000,\"height\":600,\"caption\":\"Structure of Altiratinib (shown in light blue), shown here binding to the PRP4 kinase protein in the cells of parasite Toxoplasma gondii. Credits: Christopher Swale\/IAB, Isabel Romero Calvo\/EMBL, Adobe Stock Images.\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/845a38992ad0698d457ec1dd32d13c79\",\"name\":\"Myl\u00e8ne Andr\u00e9\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9fde990ea593a68856d19cf7977a6cedcffea68f7171a1d49b0383e263032765?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9fde990ea593a68856d19cf7977a6cedcffea68f7171a1d49b0383e263032765?s=96&d=mm&r=g\",\"caption\":\"Myl\u00e8ne Andr\u00e9\"},\"url\":\"https:\/\/www.embl.org\/news\/author\/mandreembl-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Getting closer to stopping toxoplasmosis infection | EMBL","description":"Recent studies supported by EMBL Grenoble\u2019s expertise in structural biology have identified Altiratinib as a potential drug to stop toxoplasmosis infection and opened up treatment options against malaria","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/","og_locale":"en_US","og_type":"article","og_title":"Getting closer to stopping toxoplasmosis infection | EMBL","og_description":"Recent studies supported by EMBL Grenoble\u2019s expertise in structural biology have identified Altiratinib as a potential drug to stop toxoplasmosis infection and opened up treatment options against malaria","og_url":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2022-12-01T08:00:00+00:00","article_modified_time":"2024-08-16T21:26:16+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg","type":"image\/jpeg"}],"author":"Myl\u00e8ne Andr\u00e9","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Myl\u00e8ne Andr\u00e9","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/"},"author":{"name":"Myl\u00e8ne Andr\u00e9","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/845a38992ad0698d457ec1dd32d13c79"},"headline":"Getting closer to stopping toxoplasmosis infection","datePublished":"2022-12-01T08:00:00+00:00","dateModified":"2024-08-16T21:26:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/"},"wordCount":873,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg","keywords":["beamline","grenoble","infection biology","massif-1","mccarthy","parasite","structural biology","technology","toxoplasma","userstory","x-ray crystallography"],"articleSection":["Science","Science &amp; Technology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/","url":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/","name":"Getting closer to stopping toxoplasmosis infection | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg","datePublished":"2022-12-01T08:00:00+00:00","dateModified":"2024-08-16T21:26:16+00:00","description":"Recent studies supported by EMBL Grenoble\u2019s expertise in structural biology have identified Altiratinib as a potential drug to stop toxoplasmosis infection and opened up treatment options against malaria","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/science\/getting-closer-to-stopping-toxoplasmosis-infection\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg","width":1000,"height":600,"caption":"Structure of Altiratinib (shown in light blue), shown here binding to the PRP4 kinase protein in the cells of parasite Toxoplasma gondii. Credits: Christopher Swale\/IAB, Isabel Romero Calvo\/EMBL, Adobe Stock Images."},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/845a38992ad0698d457ec1dd32d13c79","name":"Myl\u00e8ne Andr\u00e9","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9fde990ea593a68856d19cf7977a6cedcffea68f7171a1d49b0383e263032765?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9fde990ea593a68856d19cf7977a6cedcffea68f7171a1d49b0383e263032765?s=96&d=mm&r=g","caption":"Myl\u00e8ne Andr\u00e9"},"url":"https:\/\/www.embl.org\/news\/author\/mandreembl-fr\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2022\/11\/20220913_TGondii_final_1000x600.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/54616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/104"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=54616"}],"version-history":[{"count":15,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/54616\/revisions"}],"predecessor-version":[{"id":59981,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/54616\/revisions\/59981"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/54668"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=54616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=54616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=54616"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=54616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}